semaglutide fda update Novo Nordisk has announced that the has approved the Wegovy® pill (once-daily oral 25 mg) as the first ever oral GLP-1 receptor agonist therapy for chronic weight management in adults FDA Clears Semaglutide For Cardiac

Management of antiplatelets in an acute setting Key Concept: Platelets should be administered in the setting of severe LGIB to maintain a platelet count of .30 3 109 /L, and a higher threshold of .50 3 109 /L can be considered if endoscopic procedures are required

Making changesespecially with medicationcan feel overwhelming at first

Precision matters: Use accurate syringes and careful calculations

We can see that the secretion of GLP-1 increases after adding berberine (Figure 6B)

Ozempic, the brand name for semaglutide, is primarily designed to help manage type 2 diabetes specifically in folks who also may benefit from weight loss

Aging and developmental transitions in the B cell lineage